SPECIALTY TOPICS

CURRENTLY VIEWING
Head & Neck Cancers

Head & Neck Cancers

Frontline Avelumab Falls Short in Phase III Head and Neck Cancer Study

The phase III JAVELIN Head and Neck 100 trial has been terminated after an interim analysis showed that the addition of avelumab to standard-of-care chemoradiotherapy was unlikely to lead to a statistically significant improvement in progression-free...
Read More >>

FDA Grants Breakthrough Designation to Debio 1143 in Frontline Head and Neck Cancer

Remote Monitoring Enhances Care for Patients With Head and Neck Cancer

FDA Grants Priority Review to Selpercatinib for RET Fusion+ NSCLC and Thyroid Cancers

NICE Rejects Treatments for Head and Neck Cancer and AML

Frontline Pembrolizumab Regimens Receive Japanese Approval in Head and Neck Cancer

View More Stories >>

View Conference Coverage

2020 School of Gastrointestinal Oncology

2020 New York GU

2020 Miami Breast Cancer Conference

2020 HCC-TAG Conference

2020 International Congress on Hematologic Malignancies

Dr. Ferris on Combining STING Agonists With Checkpoint Inhibitors in Head and Neck Cancer

Dr. Gross on the Prognosis of Cutaneous Squamous Cell Carcinoma of the Head and Neck

Dr. Saba on Immunotherapy/Radiation Combo in Head and Neck Cancer

Dr. Saba on Anticipated Research in Head and Neck Cancer

Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

Dr. Saba Discusses Ongoing Research in Head and Neck Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Key Points for Treatment of Advanced HNSCC

Next Steps in Research for Immunotherapy for HNSCC

Immunotherapy in the Peri-Operative Setting of HNSCC

Emerging Checkpoint Inhibitors for HNSCC

Take-Home Messages: Immunotherapy for HNSCC

Practical Issues Surrounding Immunotherapy for HNSCC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Notable RET Inhibitor Trials Underway

The Next Steps in RET Inhibitor Research

Using RET Inhibitors in Clinical Practice

RET Inhibitor Trial Updates at ASCO and ESMO

How BLU-667 Has Changed the Treatment Landscape

LOXO-292 in Patients With RET-Fusion Lung Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Program

Treatment of Advanced Head & Neck Squamous Cell Carcinoma

Ezra Cohen, MD; Robert Ferris, MD, PhD, FACS; and Jared Weiss, MD, provide a comprehensive overview of diagnosis and treatment of advanced head and neck squamous cell carcinoma (HNSCC), including multidisciplinary care and emerging evidence surrounding novel therapies. Treatment approaches to HPV-positive and HPV-negative tumors are explored.

Treating Advanced Differentiated Thyroid Cancer

Although most patients with differentiated thyroid cancer have an excellent prognosis, a subset of these patients will develop a more aggressive, refractory phenotype. This OncLive Peer Exchange moderated by R. Michael Tuttle, MD, focuses the latest information about how to use available therapies and the path forward to a more personalized approach for patients. The expert panel of endocrinologists and oncologists includes Marcia S. Brose, MD, PhD; Naifa Busaidy, MD, FACP, FACE; Eric J. Sherman, MD; and Francis Paul Worden, MD.
View Now